Louisbourg Investments Inc. Takes $150,000 Position in Qiagen N.V. $QGEN

Louisbourg Investments Inc. acquired a new stake in Qiagen N.V. (NYSE:QGEN) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 3,131 shares of the company’s stock, valued at approximately $150,000.

Several other large investors also recently modified their holdings of QGEN. SVB Wealth LLC bought a new stake in shares of Qiagen in the 1st quarter valued at approximately $31,000. Farther Finance Advisors LLC grew its stake in shares of Qiagen by 400.5% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock valued at $51,000 after purchasing an additional 849 shares during the period. Hilltop National Bank acquired a new position in shares of Qiagen in the 2nd quarter worth approximately $66,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of Qiagen in the 1st quarter worth approximately $94,000. Finally, GAMMA Investing LLC boosted its holdings in shares of Qiagen by 93.9% in the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock worth $118,000 after acquiring an additional 1,425 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors.

Qiagen Price Performance

NYSE:QGEN opened at $46.93 on Friday. The stock’s fifty day moving average price is $47.11 and its two-hundred day moving average price is $45.50. Qiagen N.V. has a 52-week low of $37.63 and a 52-week high of $51.88. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The company has a market cap of $10.43 billion, a price-to-earnings ratio of 27.73, a P/E/G ratio of 2.46 and a beta of 0.66.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.60. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The firm had revenue of $533.54 million for the quarter, compared to the consensus estimate of $523.97 million. During the same quarter in the prior year, the business earned $0.55 EPS. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, analysts anticipate that Qiagen N.V. will post 2.26 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Weiss Ratings reissued a “hold (c+)” rating on shares of Qiagen in a report on Wednesday. Cowen reissued a “hold” rating on shares of Qiagen in a report on Thursday, August 7th. Wall Street Zen downgraded Qiagen from a “buy” rating to a “hold” rating in a report on Saturday. UBS Group boosted their target price on Qiagen from $48.00 to $50.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Finally, Bank of America boosted their target price on Qiagen from $50.00 to $53.00 and gave the stock a “buy” rating in a report on Thursday, June 26th. Three analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $49.40.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.